Find out who stays involved after the visit

• What change are we looking for, and how will we discuss it?
• When do we next speak, and with whom?
• How do I describe a problem between visits?
• What happens if the proposed treatment is not helping?

Ask for the answers in the written plan. If a membership includes follow-up, ask what that word covers: messages, visits, reviews or something else.

• Keep the label and packaging information available for the pharmacist or the person treating you.
• Ask for clarification when the written information and the conversation seem different.

When delivery is warm or cooling has been inadequate, leave a GLP-1 injection unused, FDA advises. These weight or diabetes medicines can lose quality in those conditions.

Patients can submit medicine concerns to MedWatch, FDA’s reporting programme; reporting is also open to health professionals.

A report records a suspected problem; it does not prove that a medicine caused it.

• If you change services, ask how to obtain the care summary and relevant results.
• If you leave a membership, ask what follow-up remains available and what it costs.
• Write down the next agreed step and who is responsible for it.